Ozempic-maker's shares plunge after failed Alzheimer's trial

Ozempic-maker's shares plunge after failed Alzheimer's trial

Investors take the value of the company's shares back to where they stood in July 2021 following Novo Nordisk's announcement.

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

Ozempic-maker's shares plunge after failed Alzheimer's trial

Shares in Novo Nordisk, the Danish firm best known for its Wegovy and Ozempic weight loss drugs, have plunged after it called a halt to closely-watched trials on a treatment for Alzheimer’s disease. The company had been testing whether a key ingredient in the drugs could slow progression of the brain disorder. Novo Nordisk, which began the trials two years ago, had always treated the study as an outside bet but one which had the potential to lan…

Ozempic-maker's shares plunge after failed Alzheimer's trial | Money News | Tech, Entertainment, Sport, Fashion, Travel News

Shares in Novo Nordisk, the Danish firm best known for its Wegovy and Ozempic weight loss drugs, have plunged after it called a halt to closely-watched trials on a treatment for Alzheimer’s disease. The company had been testing whether a key ingredient in the drugs could slow progression of the brain disorder. Novo Nordisk, which began the trials two years ago, had always treated the study as an outside bet but one which had the potential to lan…